Related Experiment Video
Updated: Apr 24, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation
Philippe Moreau1, Cyrille Hulin2, Thierry Facon3
1Hematology Department, UMR892, University Hospital, Place Ricordeau, Nantes 44093, France.
Abstract:
Considerable progress has been recently made in the treatment of elderly patients with multiple myeloma (MM). In Europe the combination of thalidomide with melphalan and prednisone and of bortezomib with melphalan and prednisone are 2 standards of care for frontline therapy for elderly patients. In United States the combination of lenalidomide and dexamethasone is the preferred option in this setting. This article focuses on more recent therapeutic approaches in older MM patients, not eligible for high-dose therapy and autologous stem cell transplantation.
More Related Videos
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Tumor Immunotherapy